Mexico Montelukast Api Market Size, Share, Trends and Forecasts 2031

Key Findings

• The Mexico Montelukast API Market is expanding steadily due to increasing global demand for anti-asthmatic and anti-allergic drugs.
• Rising incidence of asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis is driving the need for Montelukast-based formulations in Mexico.
• Growing adoption of generic drugs and the expiry of key patents have opened significant opportunities for API manufacturers.
• Technological advancements in synthesis, purification, and continuous manufacturing processes are improving yield and purity of Montelukast API.
• Increasing regulatory approvals for Montelukast generics in emerging markets are boosting supply chain growth.
• The presence of strong pharmaceutical manufacturing infrastructure in Mexico is supporting large-scale API production and export.
• Price fluctuations of raw materials and stringent quality standards remain major challenges for smaller producers.
• Strategic alliances, mergers, and capacity expansions among API producers are shaping competitive dynamics across Mexico.

Mexico Montelukast API Market Size and Forecast

The Mexico Montelukast API Market is projected to grow from USD 450 million in 2025 to USD 810 million by 2031, registering a CAGR of 10.2% during the forecast period. The rise in respiratory diseases, increasing healthcare access, and growth in the generic pharmaceutical industry are key factors driving market expansion. In Mexico, Montelukast API is extensively used in the production of tablets, chewable tablets, and oral granules for asthma and seasonal allergies. Pharmaceutical companies are investing in advanced synthesis technologies to optimize production efficiency and comply with regulatory standards such as cGMP and ICH guidelines. Additionally, favorable government policies promoting domestic pharmaceutical manufacturing and exports are expected to further strengthen the market outlook through 2031.

Introduction

Montelukast is a leukotriene receptor antagonist (LTRA) primarily used in the management of asthma and allergic rhinitis. Its active pharmaceutical ingredient (API) serves as the core raw material in the formulation of various dosage forms under multiple brand and generic names. The molecule acts by inhibiting leukotriene D4, reducing inflammation and bronchoconstriction in the respiratory tract. In Mexico, the growing pharmaceutical manufacturing ecosystem and increased prevalence of respiratory ailments are driving sustained demand for Montelukast API. Manufacturers are focusing on optimizing synthesis routes, reducing production costs, and maintaining strict compliance with international pharmacopeia standards to ensure global competitiveness.

Future Outlook

By 2031, the Mexico Montelukast API Market is expected to be characterized by expanded production capacity, improved process efficiency, and stronger export orientation. Increasing adoption of automated and continuous-flow synthesis technologies will enhance yield consistency and environmental sustainability. Manufacturers will focus on eco-friendly processes to meet global green chemistry requirements. Furthermore, as governments encourage self-reliance in pharmaceutical ingredients, regional API suppliers in Mexico will play a vital role in reducing dependency on imports. The shift toward integrated API-to-formulation production lines will improve cost-effectiveness and supply chain resilience. Strategic collaborations with multinational pharmaceutical companies will help local producers meet global regulatory and quality standards.

Mexico Montelukast API Market Trends

• Rising Demand for Anti-Asthma and Anti-Allergy Drugs
  The prevalence of asthma and allergic rhinitis is increasing rapidly in Mexico due to urban pollution, lifestyle changes, and environmental allergens. Montelukast-based drugs are being prescribed as first-line therapy for chronic respiratory management. With rising awareness of respiratory health, demand for both branded and generic formulations continues to rise. This sustained pharmaceutical demand is directly driving the requirement for Montelukast API production and bulk supply.

• Growth in Generic Drug Manufacturing
  Patent expiries for Montelukast formulations have spurred generic manufacturing in Mexico, leading to higher consumption of the API. Local and regional pharmaceutical firms are investing in Montelukast API production to serve both domestic and international markets. Governments are supporting this trend through incentives for bulk drug parks and reduced import duties on process equipment. This proliferation of generic manufacturers is intensifying competition while expanding the overall market base.

• Technological Advancements in API Synthesis
  Continuous-flow chemistry, catalytic synthesis, and green solvent technologies are transforming Montelukast API production in Mexico. These methods improve reaction efficiency, reduce waste generation, and enhance product quality. Companies adopting process intensification technologies are achieving better yields and lower operational costs. This innovation-driven trend is positioning Mexico as a regional hub for high-quality API manufacturing.

• Regulatory Compliance and Quality Standardization
  Regulatory compliance has become a critical differentiator in the Montelukast API Market. In Mexico, manufacturers are increasingly adhering to Good Manufacturing Practices (GMP), ICH Q7 guidelines, and pharmacopeial standards such as USP and EP. Regular audits by agencies like the FDA and EMA have elevated production standards. Companies that maintain high compliance levels are securing long-term supply contracts with global pharmaceutical firms.

• Increasing API Export and Strategic Partnerships
  Export-oriented growth is emerging as a dominant trend in Mexico’s Montelukast API industry. Manufacturers are entering into partnerships with international distributors and formulation companies to expand global reach. Rising demand in markets such as North America, Europe, and Asia-Pacific is boosting export revenues. Strategic collaborations also enable technology transfer and shared innovation in synthesis and quality control processes.

Market Growth Drivers

• High Prevalence of Respiratory Disorders
  The growing burden of asthma, COPD, and allergic rhinitis in Mexico has created strong pharmaceutical demand for Montelukast. The increasing use of Montelukast as both standalone therapy and combination medication is accelerating API production. Seasonal variations, pollution, and climate changes are further expanding the patient population requiring long-term anti-leukotriene therapy.

• Expanding Generic Pharmaceutical Production
  The surge in generic drug manufacturing following patent expirations has significantly increased Montelukast API consumption. In Mexico, favorable industrial policies and financial incentives for local producers are encouraging investment in API plants. The ability to produce high-quality Montelukast at competitive costs is helping manufacturers capture both domestic and export market share.

• Government Support for Domestic API Manufacturing
  Governments in Mexico are implementing policies to promote self-reliance in pharmaceutical ingredients. Financial support, tax exemptions, and the establishment of dedicated pharmaceutical parks are fostering local API production. This initiative reduces import dependency and ensures consistent raw material availability for formulation manufacturers, strengthening the overall supply chain.

• Technological Integration and Process Optimization
  The integration of advanced manufacturing technologies, including process analytical control (PAT) and automation, is improving yield, efficiency, and reproducibility in Montelukast production. Companies adopting real-time monitoring and continuous synthesis are achieving significant reductions in waste and batch rejection rates. These improvements enhance profitability and ensure consistent product quality for regulatory compliance.

• Rising Export Demand and Trade Liberalization
  Mexico’s competitive labor costs, improving regulatory environment, and proximity to major pharmaceutical markets are driving export growth. Free trade agreements and bilateral partnerships with key economies are facilitating smoother access to regulated markets. As global pharmaceutical firms seek cost-efficient sourcing partners, Mexico’s Montelukast API suppliers are well-positioned to meet international demand.

Challenges in the Market

• Volatility in Raw Material Prices
  The synthesis of Montelukast API requires specialized intermediates and reagents, which are subject to price fluctuations. In Mexico, dependency on imported raw materials exposes manufacturers to supply chain instability and cost pressures. Establishing localized supply networks and backward integration is crucial to mitigate these challenges.

• Stringent Regulatory Approval Processes
  Compliance with stringent global regulatory frameworks can delay market entry for API manufacturers. In Mexico, companies must obtain approvals from multiple agencies such as USFDA, EMA, and local authorities. Lengthy certification timelines and high compliance costs can deter smaller producers from scaling operations.

• High Production and Environmental Costs
  Montelukast API production involves complex multi-step chemical synthesis and solvent recovery, resulting in high operational expenses. Environmental regulations concerning solvent emissions and effluent disposal further increase costs. Implementing green chemistry and solvent recycling systems is essential for sustainable manufacturing.

• Competition from Established Global Players
  The Montelukast API Market in Mexico faces intense competition from multinational producers with large-scale facilities and advanced technology. These global companies benefit from economies of scale and established distribution networks, posing challenges to local manufacturers. Strategic differentiation through quality, reliability, and cost efficiency is necessary to remain competitive.

• Patent Litigation and Intellectual Property Barriers
  Although major patents have expired, certain process patents and formulation rights remain active in key markets. Legal disputes over process infringement and API purity can delay product approvals and exports. In Mexico, companies must invest in strong intellectual property (IP) management and adopt alternative synthesis routes to navigate these constraints.

Mexico Montelukast API Market Segmentation

By Purity Type

• 98% Purity

• 99% Purity

   

By Application

• Asthma Treatment

• Allergic Rhinitis

• Bronchoconstriction Management

• Chronic Obstructive Pulmonary Disease (COPD)

• Others

By End-User

• Pharmaceutical Formulation Companies

• Contract Manufacturing Organizations (CMOs)

• Research Laboratories

• Academic and Clinical Research Institutes

By Distribution Channel

• Direct Sales

• Distributors and Traders

• Online Pharmaceutical Suppliers

Leading Key Players

• Teva Active Pharmaceutical Ingredients (TAPI)

• Dr. Reddy’s Laboratories Ltd.

• Cipla Ltd.

• Sun Pharmaceutical Industries Ltd.

• Aurobindo Pharma Ltd.

• Zhejiang Huahai Pharmaceutical Co., Ltd.

• Hetero Drugs Ltd.

• Jubilant Pharmova Ltd.

• Apotex Pharmachem Inc.

• Lupin Limited

Recent Developments

• Teva API expanded production capacity in Mexico to meet rising global demand for Montelukast raw materials.

• Dr. Reddy’s Laboratories Ltd. introduced a new cost-efficient synthesis route to reduce environmental waste in Montelukast API production.

• Aurobindo Pharma Ltd. announced long-term supply agreements with major formulation companies in Mexico for Montelukast-based products.

• Zhejiang Huahai Pharmaceutical Co., Ltd. launched an automated process control system to ensure consistent purity and regulatory compliance.

• Cipla Ltd. partnered with regional CMOs in Mexico to scale up Montelukast API production for emerging markets.

This Market Report Will Answer the Following Questions

1. What is the projected size and growth rate of the Mexico Montelukast API Market by 2031?

2. Which technological advancements are shaping API synthesis and purification in Mexico?

3. What are the major drivers and barriers influencing Montelukast API production and trade?

4. How are local manufacturers competing with global players in terms of quality and cost efficiency?

5. Which companies are leading innovation and regulatory compliance in the Montelukast API segment across Mexico?